Cosmo Bio Co

Cosmo Bio Co Intangible Assets

The Intangible Assets of Cosmo Bio Co (3386.T) as of Oct 26, 2026 is 167.00 M JPY. In the previous year, Intangible Assets was 162.00 M JPY — a change of 3.09% (higher).

Intangible Assets

167.00 MJPY

YoY

3.09%

Last updated:

Intangible Assets of Cosmo Bio Co is 2025 167.00 M JPY. Intangible Assets of Cosmo Bio Co was 2024 162.00 M JPY. It decreases by 3.09% higher compared to the previous year.

The Cosmo Bio Co Intangible Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Intangible Assets
Date
Intangible Assets
Jan 1, 2018
252.00 M JPY
Jan 1, 2019
199.00 M JPY
Jan 1, 2020
165.00 M JPY
Jan 1, 2021
182.00 M JPY
Jan 1, 2022
171.00 M JPY
Jan 1, 2023
155.00 M JPY
Jan 1, 2024
162.00 M JPY
Jan 1, 2025
167.00 M JPY
The Cosmo Bio Co Intangible Assets history
YEARIntangible AssetsYoY
167.00 MJPY+3.09%
162.00 MJPY+4.52%
155.00 MJPY-9.36%
171.00 MJPY-6.04%
182.00 MJPY+10.30%
165.00 MJPY-17.09%
199.00 MJPY-21.03%
252.00 MJPY+1.20%
249.00 MJPY-9.78%
276.00 MJPY+23.21%
224.00 MJPY+126.26%
99.00 MJPY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cosmo Bio Co Stock analysis

What does Cosmo Bio Co do? Cosmo Bio Co., Ltd. generates revenue through the export, import, and sale of bio-research reagents, instruments, and software, as well as clinical diagnostics. The company imports research reagents primarily from the United States and Europe, which are utilized in life science research. In the equipment segment, Cosmo Bio handles specialized life science research equipment sourced from domestic and overseas suppliers, targeting domestic market sales. The equipment includes ultrasonic cell disruption devices, bioimaging systems, and research consumables. Clinical test drugs are sold mainly to hospitals and testing centers. The company's research reagents business focuses on importing products from the United States and Europe, which are prioritized for life science research applications. Equipment sales target domestic customers seeking specialized life science research tools, including ultrasonic cell disruption equipment and bioimaging-related devices. Clinical diagnostics products are distributed to hospitals and testing centers for medical testing purposes. Cosmo Bio's revenue streams are divided into three main segments: bio-research reagents, life science equipment, and clinical diagnostics. The reagents segment relies on imports from the United States and Europe, while the equipment segment features products like ultrasonic cell disruption equipment and bioimaging systems. Clinical diagnostics products are sold to hospitals and testing centers as test drugs for medical use. Cosmo Bio Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Cosmo Bio Co stock

Intangible Assets of Cosmo Bio Co is 167.00 M JPY in 2025.

Intangible Assets of Cosmo Bio Co changed from 162.00 M JPY to 167.00 M JPY, representing a 3.09% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Intangible Assets Cosmo Bio Co since 2006 – with annual values, charts, and detailed analysis.

Intangible assets are non-physical assets such as patents, trademarks, copyrights, and software. They can be significant value drivers for technology and pharmaceutical companies.

Intangible Assets's JPY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Intangible Assets's Cosmo Bio Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Cosmo Bio Co

All Key Metrics — Cosmo Bio Co